AFT signs new licensing agreement for ZENEO(R) Midazolam

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com





21 July 2023

AFT signs new licensing agreement for ZENEO®
Midazolam
AFT Pharmaceuticals (ASX: AFP, NZX: AFT) announces in licensing for Australia and
New Zealand of Zeneo Midazolam for epilepsy rescue therapy from Crossject, Dijon,
France.
Full details are in the attached release from Crossject.
“We are very pleased to partner with Crossject to bring ZENEO® Midazolam to our
home markets, said Dr Hartley Atkinson. This ground-breaking needle-free system for
rapidly and easily administering a life-saving drug to epileptic patients will fulfill an
existing need for the treatment of epileptic seizures. Crossject’s ZENEO® technology
represents a natural fit with our longstanding commitment to innovation.
“This is one of the products we identified for our extensive NPD pipeline to fuel our
continued growth in our home markets.”

Released for and on behalf of AFT Pharmaceuticals limited by Malcolm Tubby, Chief
Financial Officer.

For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

About AFT Pharmaceuticals (ASX:AFP, NZX:AFT)
www.aftpharm.com

AFT Pharmaceuticals are a growing multinational pharmaceutical company that
develops, markets, and distributes a broad portfolio of pharmaceutical products
across a wide range of therapeutic categories which are distributed across all major
pharmaceutical distribution channels: over the counter, prescription, and hospital.
AFT Pharmaceutical's product portfolio comprises both proprietary and in -licensed
products, and includes patented, branded, and generic drugs.

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com








Press Release
Crossject signs new licensing agreement on
ZENEO® Midazolam epilepsy rescue therapy
with AFT Pharmaceuticals for Australia &
New Zealand



Exclusive licensing, distribution and promotion agreement for ZENEO® Midazolam in epileptic
seizures in Australia and New Zealand
Pre-marketing payments of about €0.5m due to Crossject from AFT
Dijon, France 20 July 2023 -- Crossject (ISIN: FR0011716265; Euronext:ALCJ), a specialty
pharma company that develops and will soon market a portfolio of drug device combinations
for use in emergency situations, announces the signing of an Australia & New Zealand
commercial agreement for ZENEO® Midazolam, its innovative rescue treatment of epileptic
seizures.


‘‘We are pleased to expand our ongoing international roll-out of ZENEO® Midazolam to treat
certain epileptic crisis into Australia and New Zealand, with this licensing agreement,” said
Patrick Alexandre, CEO of Crossject. “AFT Pharmaceuticals is a particularly well suited partner
for us in Australasia because of its strong presence in the region and extensive experience with
successful commercial launches. We look forward to collaborating to ensure a strong launch for
our exciting innovative needle-free emergency treatment for epileptic crisis.’’

Intramuscular Midazolam is the gold standard to treat patients in the case of certain
epileptic seizures
1
that represent a life-threatening situation. The current solutions can be
challenging for non-healthcare-professionals to administer during an emergency. There is a
clear need for a simple and dependable needle-free way to administer an emergency
treatment for epilepsy. The simplicity of use of ZENEO® (see “Intuitive” study
2
), will afford
patients and their caregivers a needle-free injection technology that delivers life-saving
medicine in less than 1/10th second.

“We are very pleased to partner with Crossject to bring ZENEO® Midazolam to our core market,”

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

said Dr Hartley Atkinson, CEO of AFT Pharmaceuticals. ‘‘ This ground-breaking needle-free
system for rapidly and easily administering a life-saving drug to epileptic patients will fulfill an
existing need for the treatment of epileptic seizures. Crossject’s ZENEO® technology represents a
natural fit with our longstanding commitment to innovation.”

Under the terms of the agreement, AFT will be responsible for all local regulatory and
commercial activities. In exchange for the commercial rights, Crossject shall receive: about
€0.5m (AUD 0.79m) of premarketing payments from AFT. About €150k (AUD 237k) is due
after the signature of the agreement. The remainder consists of development and approval
milestones. Crossject will manufacture and sell the product to AFT at a mid-double-digit
percentage of AFT’s net selling price to wholesalers, with a minimum floor price per unit.
Filing for marketing approval to Australia and New Zealand regulatory authorities is
expected a few months after filing in Europe.

Epilepsy is the fourth most common neurological disorder in the world, affecting roughly 1
in 26 people, according to the Epilepsy Foundation. The disorder affects people of all
genders, races, ethnic backgrounds and ages. It causes surges of electrical activity in the
brain that can cause recurring seizures.

Epilepsy afflicts an estimated 151,000 people in Australia
3
and an estimated 50,000 people
in New Zealand
4
.

Crossject SA (Euronext:ALCJ; www.crossject.com) is developing and will soon market a
portfolio of drugs for use in emergency situations (epilepsy, overdose, allergic shock, severe
migraine and asthma attack). With its patented needle-free self-injection system, Crossject
aims to become the world leader in self-administered emergency medications. The
company has been listed on the Euronext Growth market in Paris since 2014, and benefits
from Bpifrance funding.

AFT Pharmaceuticals Limited (ASX: AFP & NZX:AFT) is a specialty pharmaceutical company
operating primarily in Australasia, but with product distribution agreements worldwide. The
company's product portfolio includes prescription and over-the-counter medicines to treat a
range of conditions, as well as a patented nebulizer.

For further information, please contact:

Crossject
Patrick Alexandre
Chief Executive Officer
info@crossject.com
Investors
Natasha Drapeau
Cohesion Bureau
+41 76 823 75 27
natasha.drapeau@cohesionbureau.com

Media
Sophie Baumont
Cohesion Bureau
+33 6 27 74 74 49
sophie.baumont@cohesionbureau.com



1
Pre-hospital midazolam for benzodiazepine-treated seizures before and after the Rapid
Anticonvulsant Medication Prior to Arrival Trial: A national observational cohort study.
2
Human factors study of ZENEO® (needle-free autoinjector) and comparison of different user
instruction formats.

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

3
Epilepsy in Australia, how many Australians have epilepsy?
4
Epilepsy consumer experience survey 2018.